BioCentury | Jul 1, 2013
Company News

Castle Biosciences sales and marketing update

...Castle launched its DecisionDx-EC in the U.S. to determine which patients with esophageal cancer will not...
...about 25% of patients have tumors that are likely to be unresponsive to chemoradiation. The DecisionDx-EC...
Items per page:
1 - 1 of 1